Personalised Risk-directed Clot Prevention For Patients With Cancer
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Blood clots are a leading cause of death among cancer patients, second only to cancer itself. This EL1 program includes clinical and laboratory studies to assess the impact of personalised clot prevention for patients receiving cancer treatments in ambulatory care settings. Laboratory studies and evaluation of outcomes among ‘real-world’ patients with cancers at high risk of developing blood clots, will improve understanding of both clots and cancer, to advance research and clinical practice.
A Study To Determine The Effects Of Heparin/ Low Molecular Weight Heparin In Neonates And Children.
Funder
National Health and Medical Research Council
Funding Amount
$193,000.00
Summary
Blood clots in newborns and children are becoming a more common problem. This is because many children with major illnesses are now surviving due to the remarkable advances in medical and surgical care. Blood clots in children can have devastating long term effects. Little is known about the best way to treat blood clots in children and most treatments are just extrapolated from adult treatment guidelines. This is unlikely to be the best treatment as the type and place of blood clots in children ....Blood clots in newborns and children are becoming a more common problem. This is because many children with major illnesses are now surviving due to the remarkable advances in medical and surgical care. Blood clots in children can have devastating long term effects. Little is known about the best way to treat blood clots in children and most treatments are just extrapolated from adult treatment guidelines. This is unlikely to be the best treatment as the type and place of blood clots in children are very different to adults. In addition, the blood clotting system in children is very different to that in adults. This is especially true for newborns. Over the last four years we have established the largest clinical treatment program for children with blood clots in Australia, and have completed the preliminary work that will enable us to now study a number of aspects of the treatment for blood clots in children. This project will specifically examine heparin and low molecular weight heparin which are the most commonly used antithrombotic (anti blood clot) drugs in children. We will determine the effect of age on the mechanism of action, the optimal drug level for treatment, the frequency of the most common side effect of heparin and do some preliminary work to determine alternative treatment options. Our study will provide the basis for more appropriate use of these drugs in children, which will improve the success of therapy and reduce the risk of complications, ultimately improving the survival and quality of life for sick children affected by blood clots.Read moreRead less
An International Randomised Trial Of Low-dose Aspirin To Prevent Recurrent Venous Thromboembolism (INSPIRE)
Funder
National Health and Medical Research Council
Funding Amount
$1,989,986.00
Summary
Patients who develop venous blood clots or pulmonary embolism, without an underyling cause, are at very high risk of recurrence once anticoagulant treatment (warfarin) is discontinued. The international INSPIRE trial is assessing whether low-dose aspirin treatment (a simple and cheap alternative to warfarin) is effective and safe in preventing further blood clots. If proven effective, aspirin could potentially prevent thousands of patients worldwide from experiencing such events.
Low-dose Aspirin To Prevent Recurrent Venous Thromboembolism (ASPIRE) Study: A Multicentre Randomised Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,108,600.00
Summary
In approximately one-third of patients who develop deep vein thrombosis or pulmonary embolism, this event is 'unprovoked' . These patients are at very high risk of recurrence once treatment with warfarin is discontinued. Warfarin treatment is very effective to prevent recurrence but is inconvenient because it has to be very closely monitored with blood tests and also causes serious bleeding complications in a significant number of patients. There are currently no other treatments available to pr ....In approximately one-third of patients who develop deep vein thrombosis or pulmonary embolism, this event is 'unprovoked' . These patients are at very high risk of recurrence once treatment with warfarin is discontinued. Warfarin treatment is very effective to prevent recurrence but is inconvenient because it has to be very closely monitored with blood tests and also causes serious bleeding complications in a significant number of patients. There are currently no other treatments available to prevent recurrent thrombosis. Low-dose aspirin treatment offers a simple, inexpensive, and widely practicable alternative to warfarin but has not yet been proven to be effective for preventing recurrent thrombosis. This study will investigate the effectiveness and safety of aspirin to prevent recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism who have completed standard anticoagulation with heparin and warfarin. If proven to be effective, aspirin could potentially prevent thousands of patients from experiencing recurrent venous thromboembolism or fatal pulmonary embolism worldwide and also save millions of dollars in health care costs each year.Read moreRead less
Australian Stroke Genetics Collaborative - Genome-wide Association Study In Ischaemic Stroke
Funder
National Health and Medical Research Council
Funding Amount
$1,141,037.00
Summary
The majority of stroke is caused by atherothrombosis, the formation of blood clots in brain blood vessels. Numerous genes are linked to atherothrombosis, but many studies examined genetic influences in isolation from environmental risk factors. We will examine the relevance of genetic variations linked to atherothrombosis, in the context of environmental risk factors. By determining the contribution of genetic and environmental factors in stroke, we will develop a stroke risk assessment tool.
Investigation Of A New Approach To Regulate Fibrin Clot Retraction And Arterial Thrombolysis
Funder
National Health and Medical Research Council
Funding Amount
$483,171.00
Summary
Pathological blood clots are removed in patients by administering clot dissolving drugs (fibrinolytics). However these drugs are quite often ineffective and cause bleeding. We have identified a new platelet-mediated pathway controlling contraction of blood clots, important for clot stability. In this proposal, we will examine the potential for inhibitors of this pathway to loosen blood clots, and facilitate the actions of fibrinolytics to promote clot dissolution.
Neurodegeneration In The Ageing Brain: How The Pathways Leading To Aggregated Protein Cause Disease
Funder
National Health and Medical Research Council
Funding Amount
$12,322,838.00
Summary
The team consists of eight highly experienced research scientists who are dedicated to solving the question of how the brain degenerates in the elderly when associated with the accumulation of certain proteins: e.g. A_ amyloid (Alzheimer�s disease) and PrP (Creutzfeldt-Jakob disease). Understanding the molecular pathways leading to the degeneration (loss of neuronal synapses) will permit the development of rational diagnostic and therapeutic interventions. Over the past five years the program ha ....The team consists of eight highly experienced research scientists who are dedicated to solving the question of how the brain degenerates in the elderly when associated with the accumulation of certain proteins: e.g. A_ amyloid (Alzheimer�s disease) and PrP (Creutzfeldt-Jakob disease). Understanding the molecular pathways leading to the degeneration (loss of neuronal synapses) will permit the development of rational diagnostic and therapeutic interventions. Over the past five years the program has identified several diagnostic and therapeutic avenues which are now being developed by the Pharmaceutical and Biotechnology industries. Much more research is still required for maximizing the chances of success using these approaches.Read moreRead less
The Prevalence And Trajectory Of Kidney Disease In Urban Aboriginal Children
Funder
National Health and Medical Research Council
Funding Amount
$94,515.00
Summary
The Study of Environment and Aboriginal Resilience on Child Health is a major NHMRC funded project looking at the health and illness of urban Aboriginal children in Australia. By working together with Aboriginal Community Controlled Health Services across urban and large regional centres in NSW the study team hope to better understand the causes of common diseases such as kidney and heart disease, and whether these first begin in childhood.
Computational Modelling To Understand Early-stage Neurodegeneration
Funder
National Health and Medical Research Council
Funding Amount
$645,205.00
Summary
Rather than attempting to reverse neurodegeneration, therapeutic strategies must target the earliest possible stages of disease, when treatments have the potential to prevent or slow down pathological progression. The proposed project will employ computational modelling using functional MRI to deliver highly efficient and sensitive markers of Familial Alzheimer’s disease and Huntington’s disease progression to inform when in the progression of disease clinical trials should take place.